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Intracardiac thrombus, particularly in the left side of theheart, raises the concern of thromboembolism, which canresult in sudden death.1 Apart from mural thrombus in pa-tients with ischemic heart disease, thrombi are rarely en-
countered in the left ventricle (LV), and they are common in the
left atrium. We describe a rare case of ball thrombus in the LV,
which was successfully excised. The patient had no history of
ischemic heart disease or valvular disease and had a normal sinus
rhythm. The patient’s postoperative period was complicated by a
systemic inflammatory disease, namely Sweet syndrome.2 We
present a brief review of ball thrombus in the LV, as well as a
discussion regarding its atypical association with Sweet syndrome
in this case.
Clinical Summary
A 67-year-old man had a high temperature (39°C), together with
itchy skin and a macular rash on his body. He had these symptoms
for 3 months. His medical history included only an appendectomy
6 years previously; no heart attacks were noted. On physical
examination, a grade 2/6 systolic murmur was heard at the apex of
the heart. There were no signs suggestive of ischemic heart disease
or congestive heart failure. The electrocardiogram showed a nor-
mal sinus rhythm without changes related to ischemic heart dis-
ease. Transthoracic echocardiography revealed a floating mass in
the LV and mild mitral regurgitation (Figure 1), despite good
biventricular function. The mass was 3 cm in diameter and sus-
pended by tendons from both the anterior mitral leaflet and the
anterior papillary muscle. Complete blood counts showed mild
anemia, whereas clotting test results, including prothrombin test
results, activated partial thromboplastin times, fibrinogen levels,
antithrombin III levels, D-dimer levels, and fibrin-degenerated
products were within normal limits. Liver function test results
were increased, and other laboratory examinations were as fol-
lows: C-reactive protein, 10.8 mg/dL; rheumatoid factor, 10 U/mL;
antistreptolysin-O, 286 U/mL; and interleukin 6, 12.7 pg/mL. The
possibility of imminent thromboembolism and sudden death, as
well as the concern of infective endocarditis, led to an urgent
surgical removal of the tumor. The operation was performed
through a median sternotomy by using standard cardiopulmonary
bypass. After clamping the aorta, the heart was arrested by means
of cardioplegic solution, and the left atrial cavity was explored by
opening the fossa ovalis. An encapsulated mass, measuring 3.0 
3.0  2.5 cm, was seen through the mitral orifice (Figure 2) and
excised. The attachment to the anterior mitral leaflet was sliced and
then reapproximated by using interrupted 6-0 polypropylene su-
tures. Coaptation of the mitral valve was tested by infusing saline
solution into the LV cavity; this test confirmed no regurgitation.
The cardiopulmonary bypass successfully came off with small
doses of inotropic agents. Microscopically, the mass was filled
with fibrin and red cells, which was compatible with the findings
of thrombus. No inflammatory cells had infiltrated into the throm-
bus and the capsule.
The patient’s postoperative course was uneventful until 15 days
after the operation, when he became ill, with a high temperature of
more than 39°C and macular skin rashes, and presented with an
increased liver function test result. This was the identical clinical
picture he had previously. He was started on intravenous antibi-
otics, which failed to improve his symptoms. He was then referred
to the dermatology service, which diagnosed Sweet syndrome
(acute neutrophilic febrile dermatosis). The diagnosis was con-
firmed by means of skin biopsy. An anti-inflammatory agent,
naproxen, was started, after which the patient’s condition dramat-
ically improved. Corticosteroids were not used. Scores of blood
samples were taken and sent for culture, and no organisms were
grown. Clinical work-up for inflammatory bowel disease and he-
matopoietic neoplasm were performed and found to be negative.
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Discussion
Intracardiac thrombus in the LV is not so uncommon in patients
with certain cardiac diseases, such as ischemic heart disease. The
incidence of impaired LV contractility in cases of myocardial
infarction has been reported as 8.9%.3 In our patient there was no
history of myocardial infarction and no evidence of rheumatic
valvular disease; atrial fibrillation was ruled out as well. Further-
more, most cases of thrombus in the LV are mural thrombi and not
ball thrombi. Therefore, this case is a rare presentation of LV
thrombus. The thrombus was suspended by chordae tendineae
from both the mitral valve and the papillary muscle. Paloheimo4
reported an unusual presentation of thrombus, which he supposed
had grown along a threadlike strand from the right atrium to the
right ventricle. We cannot clarify the pathogenesis in our case
because the ball thrombus was actually in the LV and not in the
right ventricle. However, a similar mechanism is suggested; that is
the thrombus seemed to have grown along the chordae tendineae
of the mitral valve.
In addition to the rarity of ball thrombus in the LV, this case
was complicated by a systemic inflammatory disease, namely
Sweet syndrome. Sweet2 first described the condition character-
ized by the sudden onset of fever, leukocytosis, and cutaneous
eruption. The eruption consists of tender, erythematous, well-
demarcated papules and plaques that show dense neutrophilic
infiltrates microscopically. This condition involves oral mucosa,
joints (arthralgia), eye, lungs, kidney, liver, bone, and the central
nervous system.5 Our patient had high fever, anemia, and skin
lesions. Despite complete blood count showing no leukocytosis, a
skin biopsy confirmed infiltration of neutrophils, which was com-
patible with the findings of Sweet syndrome. The pathogenesis of
Figure 1. Preoperative echocardiography: long-axis view from the apex. A ball-like mass floats in the LV.
Figure 2. Intraoperative photograph: surgeon’s view. A mass is seen through the mitral valve orifice.
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Sweet syndrome is still unknown; however, it is presumed to be a type
of hypersensitivity reaction that leads to stimulation of a cascade of
cytokines that precipitate neutrophil activation and infiltration.5
That is why corticosteroids and immunosuppressants have been
successfully used as treatments.6 We chose a nonsteroidal anti-
inflammatory agent over a corticosteroid or immunosuppressant.
The most frequent conditions associated with Sweet syndrome
are inflammatory bowel disease and hematopoietic neoplasm.5 A
work-up revealed that the patient did not have these diseases.
Cardiovascular involvement in Sweet syndrome is not so common.
There are a few reports of cardiovascular involvement in patients
with Sweet syndrome.7 Hayashi and associates8 reported a female
patient with Sweet syndrome who underwent aortic and mitral
valve replacement; this patient’s native valves showed no neutro-
phil infiltration. Similarly, no inflammatory cells had infiltrated
either the capsule or thrombus of our patient. We cannot find any
definite relationship between LV thrombus and Sweet syndrome,
and therefore we suggest that this is a case in which LV thrombus
and Sweet syndrome simply coincided.
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Apolipoprotein E4 increases aortic atheroma burden in cardiac surgical
patients
Lian K. Ti, MMed, G. Burkhard Mackensen, MD, Hilary P. Grocott, MD, FRCPC, Daniel T. Laskowitz, MD,
Barbara G. Phillips-Bute, PhD, Carmelo A. Milano, MD, Andrew K. Hilton, MB, BS, FANZCA, Mark F. Newman, MD,
Joseph P. Mathew, MD, and the Neurologic Outcome Research Group, Durham, NC
The increasing numbers of elderly patients undergoingcardiac surgery emphasizes the importance of identify-ing risk factors associated with adverse neurologic out-comes. Although the apolipoprotein 4 allele
(APOE*E4) has been identified as a risk factor,1 how its presence
increases neurologic risk remains uncertain. Apolipoprotein E
(ApoE) plays a key role in lipoprotein metabolism and has an
important influence on the pathophysiology of atherosclerosis.
ApoE’s 3 major alleles (APOE*E2, APOE*E3, and APOE*E4)
result in differing susceptibility to dyslipidemia, atherosclerosis,
and coronary heart disease. Therefore we sought to determine
whether the APOE*E4 allele influences aortic atheroma burden in
patients undergoing cardiac surgery.
Patients and Methods
With institutional review board approval, a comprehensive trans-
esophageal echocardiography examination was performed in 128
patients undergoing coronary artery bypass grafting surgery. For
analysis, a videotaped frame displaying the most diseased area in
each aortic segment was digitized. By tracing the outline of the
atheroma, the area subtended by the atheroma was estimated (area
of plaque). Similarly, the area of visualized aorta in the ascending
aorta and aortic arch was measured by tracing the visualized
segment of the aorta (Figure 1). The area of the visualized aorta in
the descending aorta was measured by estimating the angle ()
subtended by the vessel wall and calculated as a portion of a
circular or complete vessel ( r2  /360°; Figure 1). Atheroma
burden in each segment was then calculated as the percentage of
area of the visualized aorta containing atheroma. Genomic DNA
was used to determine APOE allele frequencies, as previously
described.2 Differences between patients with and without the
APOE*E4 allele were compared by using the Wilcoxon rank sum
test and the Fisher exact test. The association of atheroma burden
and genotype was investigated with multivariable linear regression
controlling for age, sex, and diabetes.
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